HUP0500074A2 - Kívánt részecskeméretű amorf HMG-CoA reduktáz inhibitorok és eljárás előállításukra - Google Patents

Kívánt részecskeméretű amorf HMG-CoA reduktáz inhibitorok és eljárás előállításukra

Info

Publication number
HUP0500074A2
HUP0500074A2 HU0500074A HUP0500074A HUP0500074A2 HU P0500074 A2 HUP0500074 A2 HU P0500074A2 HU 0500074 A HU0500074 A HU 0500074A HU P0500074 A HUP0500074 A HU P0500074A HU P0500074 A2 HUP0500074 A2 HU P0500074A2
Authority
HU
Hungary
Prior art keywords
coa reductase
particle size
desired particle
producing
reductase inhibitors
Prior art date
Application number
HU0500074A
Other languages
English (en)
Inventor
Acharya Poornaprajna
Joy Mathew
Ravindra Chandrappa
Madhavan Sridharan
Sambasivam Ganesh
Original Assignee
Biocon Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Limited filed Critical Biocon Limited
Publication of HUP0500074A2 publication Critical patent/HUP0500074A2/hu
Publication of HUP0500074A3 publication Critical patent/HUP0500074A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A találmány tárgya eljárás kívánt részecskeméretű, amorf HMG-CoAreduktáz inhibitorok és hidrátjaik előállítására. Az eljárás során (i)HMG-CoA reduktáz inhibitor heterogén keverékét feloldják valamelyhidroxilcsoporttal rendelkező oldószerben és (ii) az amorf HMG-CoA-reduktáz inhibitor kinyeréséhez az oldószert eltávolítják. Ó
HU0500074A 2002-03-18 2002-03-18 Amorphous hmg-coa reductase inhibitors of desired particle size and process for producing them HUP0500074A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2002/000045 WO2003078379A1 (en) 2002-03-18 2002-03-18 AMORPHOUS Hmg-CoA REDUCTASE INHIBITORS OF DESIRED PARTICLE SIZE

Publications (2)

Publication Number Publication Date
HUP0500074A2 true HUP0500074A2 (hu) 2005-05-30
HUP0500074A3 HUP0500074A3 (en) 2005-07-28

Family

ID=27840281

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0500074A HUP0500074A3 (en) 2002-03-18 2002-03-18 Amorphous hmg-coa reductase inhibitors of desired particle size and process for producing them

Country Status (16)

Country Link
US (1) US7230120B2 (hu)
EP (1) EP1485343B1 (hu)
JP (1) JP4308021B2 (hu)
KR (1) KR100828653B1 (hu)
AT (1) ATE452871T1 (hu)
AU (1) AU2002247944B2 (hu)
BR (1) BR0215644A (hu)
CA (1) CA2479005C (hu)
CZ (1) CZ2004943A3 (hu)
DE (1) DE60234868D1 (hu)
ES (1) ES2338530T3 (hu)
HR (1) HRP20040967A2 (hu)
HU (1) HUP0500074A3 (hu)
IL (1) IL164020A0 (hu)
NZ (1) NZ535910A (hu)
WO (1) WO2003078379A1 (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
FI120344B (fi) 2004-03-17 2009-09-30 Ranbaxy Lab Ltd Menetelmä amorfisessa muodossa olevan atorvastatiinikalsiumin valmistamiseksi
CA2583312A1 (en) * 2004-10-05 2006-04-13 Biocon Limited Process for the preparation of amorphous fluvastatin sodium
ES2272206T1 (es) * 2004-10-18 2007-05-01 Teva Pharmaceutical Industries Ltd. Procedimiento para la preparacion de la atorvastatina hemicalcica amorfa por disolucion de la sal en un disolvente organico que es una mezcla de un alcohol, y una cetona y/o un ester y eliminacion del disolvente.
MX2007004722A (es) 2004-10-28 2007-06-15 Warner Lambert Co Procedimiento para formar atorvastatina amorfa.
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
EP1905424A3 (en) * 2006-02-02 2008-04-30 Ranbaxy Laboratories Limited Process for the preparation of a pharmaceutical composition comprising stabilized statin particles
US8219173B2 (en) 2008-09-30 2012-07-10 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
EP2182925A2 (en) * 2007-07-27 2010-05-12 Cipla Limited Pharmaceutical compositions and process for making them
WO2010066846A2 (en) * 2008-12-11 2010-06-17 Dsm Ip Assets B.V. Method for the isolation of atorvastatin

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
SI20305A (sl) 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
JP2002539108A (ja) * 1999-03-08 2002-11-19 メルク エンド カムパニー インコーポレーテッド 結晶質水和ジヒドロキシオープンアシッドシンバスタチンカルシウム塩
US6646133B1 (en) * 2000-10-17 2003-11-11 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
HU226640B1 (en) * 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
AU2001288724A1 (en) 2000-09-06 2002-03-22 Merck & Co., Inc. Dihydroxy open-acid salt of simvastatin
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
PT1341785E (pt) 2000-11-16 2009-01-16 Teva Pharma Hidrólise de ésteres de ácidos r(r*,r*)-2-(4-fluorofenil)-beta,delta-di-hidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil]-1h-pirrole-1-heptanóico com hidróxido de cálcio
EP1406860A1 (en) 2001-07-06 2004-04-14 Teva Pharmaceutical Industries Limited Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives
HUP0401145A3 (en) 2001-07-06 2008-08-28 Ciba Sc Holding Ag Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3,5-dihydroxy heptanoic acid derivatives, and intermediates thereof
CZ2004158A3 (cs) 2001-07-06 2005-01-12 Teva Pharmaceutical Industries Ltd. Syntéza a meziprodukty derivátů 3,5-dihydroxyheptanové kyseliny
CA2450820C (en) 2001-08-16 2011-03-15 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
OA12777A (en) 2002-02-14 2006-07-06 Ranbaxy Lab Ltd Formulations of atorvastatin stabilized with alkali metal additions.

Also Published As

Publication number Publication date
CA2479005A1 (en) 2003-09-25
US7230120B2 (en) 2007-06-12
HUP0500074A3 (en) 2005-07-28
HRP20040967A2 (en) 2005-06-30
ES2338530T3 (es) 2010-05-10
ATE452871T1 (de) 2010-01-15
JP2005520830A (ja) 2005-07-14
IL164020A0 (en) 2005-12-18
AU2002247944A1 (en) 2003-09-29
KR100828653B1 (ko) 2008-05-09
KR20040101279A (ko) 2004-12-02
DE60234868D1 (de) 2010-02-04
CZ2004943A3 (cs) 2005-02-16
AU2002247944B2 (en) 2009-05-21
NZ535910A (en) 2006-04-28
US20040186162A1 (en) 2004-09-23
EP1485343A4 (en) 2006-05-31
JP4308021B2 (ja) 2009-08-05
CA2479005C (en) 2012-05-22
BR0215644A (pt) 2004-12-21
EP1485343B1 (en) 2009-12-23
WO2003078379A1 (en) 2003-09-25
EP1485343A1 (en) 2004-12-15

Similar Documents

Publication Publication Date Title
WO2004052850A3 (en) Methods and compounds producing dipeptidyl peptidase iv inhibitors and intermediates thereof
HUP0500074A2 (hu) Kívánt részecskeméretű amorf HMG-CoA reduktáz inhibitorok és eljárás előállításukra
TW200616646A (en) Synthesis of boronic ester and acid compounds
RS20060250A (en) 1-amino-2-oxy-substituted tetrahydronaphtalene derivatives, method for the production thereof, and their use as antiphlogistics
HK1089444A1 (en) Dihydropteridinones, method for the production and use thereof in the form of drugs
HUP0401724A2 (hu) Eljárás királis diol-szulfon és dihidroxi-sav típusú HMG CoA reduktáz inhibitorok előállítására
PL376524A1 (pl) Nowe hydroksyindole, ich zastosowanie jako inhibitorów fosfodiesterazy 4 i sposób ich wytwarzania
MXPA04006677A (es) Procedimiento para la preparacion de esteres de escopina.
EA200900536A1 (ru) Способ получения хиральных 8-(3-аминопиперидин-1-ил) ксантинов
IL174469A0 (en) Rearranged pentanols, a method for the production thereof, and their use as antiphlogistics
BR0313070A (pt) Métodos para preparação de um diastereÈmero desejado de uma tetraidro-beta-carbolina e para preparação de um composto
RS70904A (en) Process for preparing indolinone derivatives
AU2003232246A1 (en) Method for producing an aqueous alkali acrylate solution
WO2006134482A8 (en) Process for producing atorvastatin, pharmaceutically acceptable salts thereof and intermediates thereof
MX2007002833A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios.
MY139159A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
TW200510430A (en) Process for synthesizing β -lactamase inhibitor intermediates
AU2003232370A1 (en) 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
DE60314904D1 (de) Verfahren zur herstellung von chinoloncarboxylat-derivaten
ATE437435T1 (de) Stanzersubstrat und prozess zu seiner herstellung
AU2003254574A1 (en) Method for the production of acetylene alcohols
WO2003063820A3 (en) Demixing-stable granulate
YU88204A (sh) 1-oksa 3-aza-dibenzoazuleni kao inhibitori stvaranja faktora tumorske nekroze i međuproizvodi za njihovo pripremanje
UA85589C2 (ru) Способ получения производных замещенных тетралинов и замещенных инданов
MY139443A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished